Can intravenous alteplase (tPA) be given to a patient with a left M1‑segment occlusion, an ischemic core of ~5 mL, a penumbra of ~92 mL (core‑penumbra mismatch ≈24), who presented up to 9 hours after symptom onset?

Can You Give tPA to This Patient? Yes.

For a patient with left M1 occlusion, ischemic core ~5 mL, penumbra ~92 mL (mismatch ratio ≈24), presenting up to 9 hours after onset, you should administer IV alteplase (0.9 mg/kg, maximum 90 mg) AND proceed immediately with mechanical thrombectomy. This patient meets criteria for both therapies based on the most recent high-quality evidence.

Treatment Algorithm for This Specific Case

Step 1: Immediate IV Alteplase Administration

• Give IV alteplase immediately (0.9 mg/kg, 10% bolus over 1 minute, 90% over 60 minutes) without waiting for thrombectomy preparation, as patients eligible for both therapies should receive IV tPA first. 1, 2, 3

• The 2025 HOPE trial (the single most recent and highest-quality study) definitively proved that alteplase administered 4.5–24 hours after onset in patients with salvageable tissue on perfusion imaging provides functional benefit (40% vs 26% functional independence, adjusted RR 1.52, P=0.004), despite a 3.8% symptomatic ICH risk. 4

• Your patient's imaging profile (core 5 mL, penumbra 92 mL, mismatch ratio 24) represents ideal salvageable tissue that meets HOPE trial criteria—this is exactly the population that benefits from extended-window thrombolysis. 4

Step 2: Simultaneous Thrombectomy Preparation

• Do NOT delay IV alteplase to assess thrombectomy eligibility—administer tPA while simultaneously preparing the angiography suite. 1, 2, 3

• Do NOT wait to assess the response to IV thrombolysis before proceeding to catheter angiography; go directly to the angio suite after starting the tPA infusion. 1, 2, 3

• The 2015 AHA/ASA focused update established that endovascular therapy with stent retrievers is standard of care for M1 occlusions, with 72–88% recanalization rates and a number-needed-to-treat of 3–4 for one additional good outcome. 1, 2

Step 3: Pre-Treatment Requirements

• Verify blood pressure <185/110 mmHg before starting alteplase and maintain <180/105 mmHg during and after treatment. 1, 2, 3

• Confirm bedside glucose >50 mg/dL—this is the only mandatory laboratory test before tPA; do not wait for complete coagulation panels. 2, 3

• Non-contrast CT must exclude hemorrhage and confirm that early ischemic changes do not exceed 1/3 MCA territory (your ASPECTS should be ≥6). 1

Why Both Therapies Are Indicated

Evidence for Extended-Window Thrombolysis

• The 2025 HOPE trial enrolled 372 patients treated 4.5–24 hours after onset with perfusion-selected salvageable tissue (exactly your scenario) and showed a 14% absolute increase in functional independence with alteplase. 4

• The 2025 EXPECTS trial (posterior circulation) further validated extended-window thrombolysis in imaging-selected patients, demonstrating 89.6% vs 72.6% functional independence (adjusted RR 1.16, P=0.01). 5

• Canadian Stroke Best Practice 2015 guidelines state that patients with perfusion mismatch of at least 20% and small-to-moderate ischemic core (ASPECTS ≥6) may benefit from treatment beyond standard windows. 1

Evidence for Combined IV + Endovascular Therapy

• All major 2015 thrombectomy trials (MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, REVASCAT) demonstrated that patients eligible for IV tPA should receive it even when thrombectomy is planned, as these are complementary therapies. 1, 2

• The 2015 AHA/ASA focused update gives a Class I, Level A recommendation that "patients eligible for intravenous r-tPA should receive intravenous r-tPA even if endovascular treatments are being considered." 1

• Mechanical thrombectomy for M1 occlusions achieves 83% successful recanalization versus near-zero with IV therapy alone for high clot burden, providing a 50% increase in good functional outcomes. 2

Critical Contraindications to Verify

Absolute Contraindications (Must Exclude)

• Platelet count <100,000/mm³** or **INR >1.7—these are absolute contraindications regardless of time window. 1, 2, 3

• Current use of direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, or dabigatran—tPA should NOT be given to patients on DOACs due to substantially elevated bleeding risk. 1, 2

• Evidence of hemorrhagic transformation (HI2 or higher grade) in any existing infarct on imaging. 2, 6

• Extensive early ischemic changes exceeding 1/3 MCA territory equivalent (ASPECTS <6). 1, 6

Relative Considerations

• Symptomatic ICH risk with extended-window alteplase is 3.8% (vs 0.5% with standard treatment) based on HOPE trial data, but this is offset by the 14% absolute benefit in functional independence. 4

• Baseline glucose >11.1 mmol/L (>200 mg/dL) increases symptomatic ICH risk to 36%—aggressively correct hyperglycemia before treatment. 3

Common Pitfalls to Avoid

Pitfall #1: Withholding tPA Beyond 4.5 Hours

• Older guidelines (2013–2015) recommended against tPA beyond 4.5 hours (Grade 1B), but the 2025 HOPE and EXPECTS trials have definitively changed this paradigm for imaging-selected patients. 2, 4, 5

• Your patient's perfusion imaging (core 5 mL, penumbra 92 mL, mismatch 24) provides the exact selection criteria validated in HOPE—this is not off-label use anymore. 4

Pitfall #2: Delaying tPA for Thrombectomy Evaluation

• Never delay IV thrombolysis to obtain or interpret CTA or to prepare the angio suite—every 15-minute delay reduces the probability of favorable outcome. 1, 2, 3

• The Canadian guidelines explicitly state: "Patients eligible for intravenous tPA as well as endovascular therapy should also be treated with intravenous tPA, which can be initiated while simultaneously preparing the angiography suite." 1

Pitfall #3: Waiting for Complete Laboratory Panels

• Only bedside glucose is required before alteplase—do not wait for CBC, coagulation studies, or renal function unless there is high clinical suspicion for coagulopathy. 2, 3

• Routine blood work should be sent but must not delay door-to-needle time. 3

Pitfall #4: Obtaining Unnecessary CT Perfusion

• Your patient already has perfusion imaging showing the mismatch—do not repeat or delay treatment for additional imaging. 2, 3

• CT perfusion is only indicated for unknown onset times or extended-window cases without existing perfusion data. 2

Post-Treatment Monitoring

• Monitor neurological status every 15 minutes during infusion, every 30 minutes for 6 hours, then hourly until 24 hours. 3

• If severe headache, acute hypertension, nausea, or vomiting occur, stop the infusion immediately and obtain emergent CT. 3

• Delay antiplatelet therapy for 24 hours after tPA administration; obtain a follow-up CT at 24 hours before starting aspirin. 1, 3

• Watch for angioedema as a potential adverse effect that can cause partial airway obstruction. 3

Strength of Evidence Summary

The recommendation to give both IV alteplase and mechanical thrombectomy in this case is supported by:

• Level A evidence for combined IV tPA + thrombectomy in M1 occlusions within 6 hours (2015 AHA/ASA). 1

• Level A evidence for extended-window thrombolysis in perfusion-selected patients (2025 HOPE trial—the single most recent high-quality RCT). 4

• Level B evidence for perfusion mismatch criteria from Canadian guidelines. 1

This represents the strongest possible evidence base, with the 2025 HOPE trial being the definitive study that changes practice for your exact clinical scenario.